The Boeing Company
$205.04B- Market cap
- $161.87B
- Debt
- +$54.10B
- Cash
- −$10.92B
Capital structure 75% equity / 25% debt · EV / Revenue 2.29x · EV proxy / EBITDA proxy 32.89x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $161.87B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 ·
Decision snapshot: BA stock price vs ABT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABT's multiple
Needs ABT P/E.
Implied fair value · at BA's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 75% equity / 25% debt · EV / Revenue 2.29x · EV proxy / EBITDA proxy 32.89x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
THE BOEING COMPANY · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LOCKHEED MARTIN CORP
BA vs LMT
NORTHROP GRUMMAN CORP /DE/
BA vs NOC
GENERAL DYNAMICS CORP
BA vs GD
TEXTRON INC
BA vs TXT
Johnson & Johnson
BA vs JNJ
Medtronic plc
BA vs MDT
BECTON DICKINSON & CO
BA vs BDX
Thermo Fisher Scientific Inc.
BA vs TMO
DANAHER CORP /DE/
BA vs DHR
BOSTON SCIENTIFIC CORP
BA vs BSX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BA can sustainably expand margins and de-lever without sacrificing growth, then hold or add selectively because the current price already reflects a steep discount to implied earnings-based value; otherwise, the combination of 87.2x P/E, 4.8% margins, and 5.8x net debt/EBITDA argues for caution versus ABT.
BA’s current price of $216.14 implies $70.47 per share under the provided P/E framework, a -67.4% gap versus the market price. The valuation gap is driven by BA’s much richer earnings multiple and weaker profitability profile than ABT, even though BA trades below ABT on sales-based multiples.
Supporting Metrics